San Francisco startup Framework Therapeutics is usually working on an oral, once-every day GLP-1 drug known as GSBR-1290—the drug surpassed Wall Street’s anticipations in June whenever a mid-stage analyze confirmed normal weight loss of all over six% and it programs to start out One more mid-phase demo in direction of the tip of this yr—that